bendamustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  

184 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bendamustine / Generic mfg.
PTBCy, NCT04943757: Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

Recruiting
2
50
RoW
Bendamustine Hydrochloride, Cyclophosphamid
St. Petersburg State Pavlov Medical University
Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
12/23
12/24
FluBuBe, NCT04942730: Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation

Completed
2
50
RoW
Fludarabine, Bendamustine Hydrochloride, Busulfan, Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus 5Mg Cap
St. Petersburg State Pavlov Medical University
Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
04/24
04/24
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
CheckMate 744, NCT02927769 / 2016-002347-41: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Hourglass Feb 2021 - Dec 2021 : From CheckMate 744 trial for r/r classic hodgkin lymphoma
Checkmark FRom CheckMate 744 trial at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: FRom CheckMate 744 trial at ASH 2018 [screenshot]
Active, not recruiting
2
72
Europe, Canada, US, RoW
Nivolumab, BMS-936558, Opdivo, brentuximab vedotin, bendamustine
Bristol-Myers Squibb, Seagen Inc.
Hodgkin Disease
06/24
11/24
Prolgo-HL, NCT05757466: Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

Recruiting
2
30
RoW
Prolgolimab, Combination with prolgolimab and bendamustine
St. Petersburg State Pavlov Medical University, N.N. Petrov National Medical Research Center of Oncology
Hodgkin Lymphoma
03/24
03/25
NCT06477549: BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Recruiting
2
220
RoW
Bendamustine Hydrochloride, Ruxolitinib
St. Petersburg State Pavlov Medical University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
06/28
06/29
ZFCR/ZBR, NCT05287984: Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

Not yet recruiting
2
63
RoW
Zanubrutinib, Fludarabine, cyclophosphamide and rituximab, ZFCR regimen, Zanubrutinib, bendamustine, rituximab, ZBR regimen
Institute of Hematology & Blood Diseases Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
06/24
11/24
GOLSEEK-2, NCT06425302: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Not yet recruiting
2
90
Europe, Canada, US, RoW
Golcadomide, CC-99282, BMS-986369, Rituximab, Mabthera, Cyclophosphamide, Endoxan, Doxorubicin, Caelyx, pegylated liposomal doxorubicin, PLD, Vincristine, Prednisone, Bendamustine
Celgene
Lymphoma, Follicular
11/26
11/28
BRAWM, NCT04624906: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Active, not recruiting
2
59
Canada
Acalabrutinib, Calquence, Bendamustine, Treanda, Rituximab, Rituxan
Sunnybrook Health Sciences Centre, AstraZeneca
Waldenstrom Macroglobulinemia
12/24
03/30
NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting
2
360
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Liver Lymphoma, Mantle Cell Lymphoma
12/24
03/25
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
110
US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
12/24
12/26
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
56
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
02/25
02/27
NCT05660993: Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
50
RoW
Nivolumab
National Research Center for Hematology, Russia
Hodgkin Lymphoma
03/25
03/25
ZBR, NCT05914662: Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM

Recruiting
2
30
RoW
Zanubrutinib, Bendamustine and Rituximab
Institute of Hematology & Blood Diseases Hospital
Waldenstrom Macroglobulinemia
03/25
12/25
NCT03856216: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Recruiting
2
44
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Bendamustine, SDX-105, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
03/25
03/25
CLL2-BZAG, NCT04515238: Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Active, not recruiting
2
42
Europe
Bendamustine, Treanda, Bendeka, Obinutuzumab, GA101, Gazyvaro, Zanubrutinib, BGB-3111, Venetoclax, ABT-199, Venclyxto
German CLL Study Group
Chronic Lymphoid Leukemia
04/25
03/27
CZ-WM01, NCT05979948: A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

Recruiting
2
60
RoW
Zanubrutinib, Bendamustine, Rituximab
Shanghai Changzheng Hospital, RenJi Hospital, Huashan Hospital, Shanghai 6th People's Hospital, Huadong Hospital
Waldenström's Macroglobulinemia
04/25
12/25
FLMRD, NCT04934930: Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Recruiting
2
40
RoW
Bendamustin, Ribomustin, Obinutuzumab, Gazyva
Meir Medical Center, Rabin Medical Center, Tel-Aviv Sourasky Medical Center, Assuta Ashdod Hospital, Ziv Medical Center
Follicular Lymphoma
08/25
08/25
NCT05025423: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Recruiting
2
40
US
Venetoclax Oral Tablet [Venclexta], rituximab infusion [Rituxan], Bendamustine infusion
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AbbVie
Mantle Cell Lymphoma
09/25
09/26
ChiCTR2100047272: Chidamide or Zanubrutinib combined withPrednisone, Etoposide, and Lenalidomide as introductive treatment following CD20 antibody and Bendamustine as consolidated therapy for Relapsed or Refractory indolent B-cell non Hodgkin Lymphoma

Recruiting
2
50
 
Bendamustine combined with rituximab
The Hospital Affiliated of Qingdao University; The Hospital Affiliated of Qingdao University, The Hospital Affiliated of Qingdao University
indolent non Hodgkin B-cell Lymphoma
 
 
ChiCTR2100046858: PD-1 Antibody combined with Chidamide, Prednisone, Etoposide, and Lenalidomide as introductive treatment following PD-1 antibody combine with Pemetrexed and Pegaspargase/Bendamustine as consolidated therapy for Relapsed or Refractory Peripheral T-cell Lymphoma.

Recruiting
2
60
 
PD-1 Antibody combined with Chidamide, Prednisone, Etoposide, and Lenalidomide as introductive treatment following Pegaspargase and Pemetrexed as consolidated therapy.
The Affiliated Hospital of Qingdao University; The Hospital Affiliated of Qingdao University, The Hospital Affiliated of Qingdao University
Peripheral T-cell Lymphoma
 
 
ChiCTR2100046855: CD20 Antibody combined with Chidamide, Prednisone, Etoposide, and Lenalidomide as introduction treatment following CD20 antibody and Bendamustine as consolidated therapy for Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
135
 
Nil
The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, The Affiliated Hospital of Qingdao University
Refractory Diffuse Large B-cell Lymphoma
 
 
ChiCTR2200057539: A prospective, multicenter, one-arm, open trial of cedarbenamine in combination with prednisone, etoposide, and lenalidomide induced bendamustine in combination with CD20 monoclonal antibody consolidation in elderly/frail relapsed/refractory follicular lymphoma (FL)

Not yet recruiting
2
66
 
Chidamide, bendamustine, Lenalidomide, etoposide, prednisone +CD20 monoclonal antibody
The Hospital Affiliated of Qingdao University; The Hospital Affiliated of Qingdao University, The Hospital Affiliated of Qingdao University
Follicular lymphoma
 
 
KEsTREL-01, NCT04510636: Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Recruiting
2
37
Canada
Pembrolizumab, KEYTRUDA, Bendamustine Hydrochloride, TREANDA
University Health Network, Toronto
Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
06/26
06/26
CLSGMCLPOLA, NCT04913103: Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Polivy, Bendamustine Hydrochloride, Bendamustine Accord, Bendamustine Glenmark, Bendamustine KABI, Rituximab, Mabthera, Rixathon, Truxima
Czech Lymphoma Study Group
Lymphoma, Mantle-Cell
08/26
08/27
NCT03755804: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Recruiting
2
250
US
bendamustine, TREANDA (R), Etoposide, VP-16, Vepeside, Doxorubicin, Adriamycin (R), Bleomycin, Blenoxane (R), Vincristine, Oncovin (R), Vinblastine, Velban (R), Prednisone, Prednisolone, Filgrastim, Neupogen (R), Brentuximab Vedotin, Adcetris, Cyclophosphamide, Cytoxan (R), DTIC, DACARBAZINE (R), Dimethyl Triazeno Imidazole Carboximide, Quality of Life Measurements, Quality of Life Measurements (QOL), Radiotherapy, radiation therapy, irradiation
St. Jude Children's Research Hospital, Teva Pharmaceuticals USA, Seagen Inc.
Hodgkin Lymphoma
01/27
07/28
NCT05868395: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Recruiting
2
16
Europe
Polatuzumab, bendamustin und rituximab, Polivy, Bendamustin, Mabthera
Medical University of Vienna
Mantle-cell Lymphoma
05/27
05/27
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
NCT05245656: A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

Recruiting
2
90
RoW
RB/RBAC alternating, RB
Kim, Seok Jin
Mantle Cell Lymphoma
12/29
12/29
2011-000097-56: A randomised phase I/II trial of lenalidomide and rituximab with or withoutbendamustine in patients ≥ 18 years with relapsed follicular lymphoma

Ongoing
1/2
168
Europe, RoW
Lenalidomide (Revlimid 5 mg), Lenalidomide (Revlimid 10 mg), Lenalidomide (Revlimid 15 mg), Rituximab, Bendamustine hydrochloride 25mg (Levact), Bendamustine hydrochloride 100mg (Levact), EU/1/07/391/001, Capsule, hard, Concentrate and solvent for solution for infusion, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Revlimid 5 mg capsules, Revlimid 10 mg capsules, Revlimid 15 mg hard capsules, Mabthera, Levact
HOVON Foundation, KWF, Celgene, Mundipharma, Cancer Research UK grant (CTAAC), HOVON Foundation
Follicular lymphoma., Cancer in the lymph nodes., Diseases [C] - Cancer [C04]
 
 
NCT02056756: Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Completed
1/2
63
Europe
Carfilzomib, Krypolis
Stichting European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
09/15
01/23
2008-007246-60: Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma

Ongoing
1/2
40
Europe
Revlimid, Revlimid, Mabthera, Ribomustin, Revlimid, Mabthera, Ribomustin
Nordic Lymphoma Group
Mantle cell lymphoma
 
 
BendAlem, 2008-004987-37`ACTRN12610000060044: Bendamustine Combined with Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) – A Phase I/II Trial with Concomitant Evaluation of Safety and Efficacy

Completed
1/2
20
Europe
Bendamustin, Ribomustin, Ribomustin
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH, Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Chronic Lymphocytic Leukaemia (CLL)
 
08/12
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Active, not recruiting
1/2
56
US
Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone
Cristina Gasparetto, Celgene
Multiple Myeloma
12/16
01/25
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02678299 / 2015-000758-39: Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Active, not recruiting
1/2
60
Europe
PREBEN
University of Aarhus
Malignant Lymphoma
02/22
12/25
NCT04762745: The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1/2
56
RoW
Pomalidomide, Pomalidomide( Anyue®, Chia Tai TIANQING, China), Bendamustine, Bendamustine( Leweixin®, Chia Tai TIANQING, China), Dexamethasone
Sun Yat-sen University
Relapsed, Refractory, Multiple Myeloma
02/22
02/23
2020-002927-13: Atezolizumab treatment together with the BEGEV regimen in patients with resistant Hodgkin's lymphoma and candidates for autologous stem cell transplantation. Trattamento di atezolizumab associato a combinazione BEGEV in pazienti con linfoma di Hodgkin resistente e candidati al trapianto autologo di cellule staminali.

Not yet recruiting
1/2
140
Europe
Atezolizumab, Bendamustina, Gemcitabina, Vinorelbina, [IMP2], [IMP3], [IMP4], [IMP5], [IMP6], [IMP1], Concentrate for solution for infusion, Powder for concentrate for solution for infusion, TECENTRIQ - 840 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 40 ML, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 10 ML, Gemcitabina cloridrato, VINORELBINA ACTAVIS - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche S.p.A.
Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04897477: Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

Recruiting
1/2
30
RoW
Azacytidine, Bendamustine and Piamprizumab
Chinese PLA General Hospital
Non-hodgkin Lymphoma,B Cell
04/22
04/23
ChiCTR2200055163: A Phase Ib Study of TQ-B3525，a PI3K-α and -δ inhibitor, in Combination with Rituximab and Bendamustine in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
30
 
TQ-B3525 in combination with rituximab and bendamustine
Sichuan Cancer Hospital; Sichuan Cancer Hospital, CHIATAI TIANQING
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
 
 
2022-001040-23: Treatment of relapsed or refractory B-cell lymphoma with CAR-T therapy produced by a new technology. Tratamiento del linfoma de células B en recaída o refractario con terapia CAR-T producida por una nueva tecnología.

Not yet recruiting
1/2
27
Europe
TranspoCART19, Cyclophosphamide, Fludarabina, Bendamustina, Tocilizumab, Cetuximab, Injection/infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, , Genoxal 25mg/ml, Fludarabina Teva 25 mg/ml, Bendamustina Tillomed 2,5 mg/ml, RoActemra 20 mg/m, Erbitux 5 mg/ml
Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL, Instituto de Salud Carlos III
Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Diseases [C] - Cancer [C04]
 
 
NCI-2012-02072, NCT01664910: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Completed
1/2
27
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
06/23
06/23
NCT03739619: Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, not recruiting
1/2
54
US
Bendamustine, Bendamustine Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Emory University, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
12/24
12/24
NCT05551936: A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Recruiting
1/2
42
US
Bendamustine, Bendeka, Treanda, Rituximab, Rituxan, Tazemetostat, Tazverik
Vaishalee Kenkre, Epizyme, Inc., University of Wisconsin, Madison
Follicular Lymphoma
08/24
05/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT04022239: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting
1/2
25
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Bendamustine, SDX-105, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, CellCept, MMF, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid System Neoplasm
07/25
07/25
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
108
US
AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
Artiva Biotherapeutics, Inc.
Non Hodgkin Lymphoma
11/24
11/24
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
140
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
05/25
12/28
NCT05451771: Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Recruiting
1/2
53
US
Venetoclax Oral Tablet, 200 mg, Venclexta, FISH assay, t(11;14) FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Decadron, Hemady, Dexamethasone Oral, 20 mg, Daratumumab Injection, Darzalex, Bendamustine, Treanda, Pomalidomide, Pomalyst, Ixazomib, Ninlaro, Venetoclax MTD with Dexamethasone
Rajshekhar Chakraborty, MD, Genentech, Inc.
AL Amyloidosis
09/26
09/26
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29
NCT01479842: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Checkmark In pts with previously untreated & relapsed/refractory NHL
Oct 2014 - Oct 2014: In pts with previously untreated & relapsed/refractory NHL
Active, not recruiting
1
48
US
BTK inhibitor PCI-32765, Bruton's tyrosine kinase inhibitor PCI-32765, PCI-32765, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride, Treanda, pharmacogenomic studies, Pharmacogenomic Study, pharmacological study, pharmacological studies, laboratory biomarker analysis
Kami Maddocks, MD, Pharmacyclics LLC.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
03/14
12/24
NCT02728531: Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Completed
1
18
US
Bendamustine, Bendamustine Hydrochloride, Treanda, Rituximab, Rituxan, Cytarabine, Cytosar-U, Tarabine PFS, Pegfilgrastim, Neulasta, G-CSF, Leukapheresis, Filgrastim, Neupogen, Autologous stem cell transplant
Washington University School of Medicine
Mantle Cell Lymphoma
01/19
08/23
NCT02168140: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed
1
16
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride, Treanda
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia
04/19
09/22
BRiM Study, NCT02257242: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Completed
1
11
US
Rituximab, Rituxan, anti-CD20 antibody, Bendamustine, Treanda, Vincristine sulfate liposome injection, Marqibo
Brown University, Spectrum Pharmaceuticals, Inc, Rhode Island Hospital, The Miriam Hospital
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
08/20
11/20
NCT03524235: Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Active, not recruiting
1
30
US
Total Body Irradiation, TBI, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Bendeka; Treanda, Fludarabine, Fludara, Rituximab, Rituxan
Noah Merin, Miltenyi Biomedicine GmbH, Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
11/21
11/31
BET2017, NCT03823365: Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

Active, not recruiting
1
19
Europe
Blinatumomab Expanded T-cells (BET)
A.O. Ospedale Papa Giovanni XXIII
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
11/21
11/22
ACE-LY-106, NCT02717624: A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Checkmark Data from P1b trial for MCL
Nov 2022 - Nov 2022: Data from P1b trial for MCL
Active, not recruiting
1
72
Europe, US
Acalabrutinib in combination with BR, Acalabrutinib + BR, Acalabrutinib in combination with VR, Acalabrutinib + VR
Acerta Pharma BV, AstraZeneca
Mantle Cell Lymphoma (MCL)
06/22
08/27
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Hourglass Apr 2020 - Jun 2020 : From trial in combination with bendamustine for penta-refractory multiple myeloma
Terminated
1
15
US
Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol
Washington University School of Medicine, Sanofi
Multiple Myeloma
03/23
03/24
NCT04049825: A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Active, not recruiting
1
36
Japan
OPB-111077
Otsuka Pharmaceutical Co., Ltd.
Relapsed or Refractory Diffuse Large B-cell Lymphoma
03/25
03/25
NCT03352765: A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

Active, not recruiting
1
28
US
rituximab, bendamustine, melphalan, Autologous Stem Cell Transplantation (ASCT)
Memorial Sloan Kettering Cancer Center
Lymphoma
11/24
11/24
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL

Recruiting
1
129
US
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
03/26
03/28
NCT04809766: Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
1
15
US
Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cytophosphane, 6055-19-2, Fludarabine, Fluradosa, 21679-14-1, Bendamustine, SDX-105, 16506-27-7
Fred Hutchinson Cancer Center, Lonza Walkersville, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
06/24
06/25
NCT06241456: FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Recruiting
1
351
US
FT825, ONO-8250, Fludarabine, FLUDARA, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab
Fate Therapeutics
Advanced Solid Tumor
05/29
05/44
NCT06191887: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recruiting
1
27
US
Autologous BAFFR-targeting CAR T Cells, Autologous BAFFR-CAR T Cells, Autologous BAFFR-CAR-expressing T-cells, Bendamustine, SDX-105, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Echocardiography, EC, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Mayo Clinic
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
12/40
12/40
NCT06308978: FT819 in Moderate to Severe Active Systemic Lupus Erythematosus

Recruiting
1
32
US
FT819, Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN, Bendamustine
Fate Therapeutics
Systemic Lupus Erythematosus
09/27
09/42
NCT06138132: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Recruiting
1
12
US
KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Bendamustine
Stanford University, Kyverna Therapeutics
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
06/27
06/27
NCT03295240 / 2006-004034-32: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Completed
1
10
US
BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax)
Memorial Sloan Kettering Cancer Center
Mantle Cell Lymphoma, Lymphoma
01/24
01/24
NCT04629729: FT819 in Subjects With B-cell Malignancies

Recruiting
1
396
US
FT819, Cyclophosphamide, Fludarabine, Fludara, IL-2, Interleukin-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
09/24
09/39
NCI-2021-03969, NCT04892277: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Recruiting
1
25
US
Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Autologous CAR-T Cells IC19/1563, CD19-directed CAR-T Cells IC19/1563, IC19 1563, IC19-1563, IC19/1563, Bendamustine, SDX-105, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, Fludarabine, Fluradosa, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Mayo Clinic, National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
12/24
12/25
NCT05950334: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Recruiting
1
322
US
FT522, Rituximab, RITUXAN, TRUXIMA, RUXIENCE, RIABNI, Cyclophosphamide, Fludarabine, Bendamustine
Fate Therapeutics
Relapsed/Refractory B-Cell Lymphoma
06/29
06/44
CC-95266-MM-001, NCT04674813: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1
180
US
CC-95266, Fludarabine, Cyclophosphamide, Bendamustine
Juno Therapeutics, a Subsidiary of Celgene
Multiple Myeloma
06/25
06/25
NCT02996773: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Active, not recruiting
1
50
US
Bendamustine, BEN, Cyclophosphamide, CY
University of Arizona
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma, High Risk Undifferentiated Acute Leukemia
08/25
08/25
NCT06043713: Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Recruiting
1
24
US
Bendamustine, SDX-105, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Echocardiography, EC, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, T-cell Receptor-engineered T-cells, T-cell Receptor-engineered T Cells, T-cell Receptor-engineered T-lymphocytes, TCR T Cells, TCR T-cells, TCR-engineered T-cells, TCR-modified T Cells
Fred Hutchinson Cancer Center, Affini-T Therapeutics, Inc.
Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
12/25
12/25
LCCC 1606-ATL, NCT03602157: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Recruiting
1
59
US
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine, Fludarabine
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center, Stand Up To Cancer
Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
09/26
09/41
NCT06094842: Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Not yet recruiting
1
20
US
Bendamustine, SDX-105, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Bridge Therapy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Echocardiography, EC, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, T-cell Receptor-engineered T-cells, T-cell Receptor-engineered T Cells, T-cell Receptor-engineered T-lymphocytes, TCR T Cells, TCR T-cells, TCR-engineered T-cells, TCR-modified T Cells, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
Fred Hutchinson Cancer Center, Bristol-Myers Squibb
Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
03/28
03/28
HL_PR/R-B, NCT06295211: Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.

Completed
N/A
32
NA
observational
Federico II University
Hodgkin Lymphoma
09/23
02/24
ChiCTR2100045050: A prospective research: in the PTCY regimen, Bendamustine was used to replace Fludarabine for haploid hematopoietic stem cell transplantation.

Recruiting
N/A
40
 
Bendamustine+Busulfan ;Fludarabine+Busulfan
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University; Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Special Project of Science and Technology Innovation for Social Undertakings and People's Livelihood Security (cstc2017shmsA130084)
Hematological Disease
 
 
NCT05813132: BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Completed
N/A
60
RoW
BEAM Protocol, (Bendamustine, Etoposide, Cytarabine, Melphalan, CEM protocol, (Carboplatin, Etoposide, Melphalan)
Rehab Werida
Lymphoma
09/23
12/23
NCT06245629: Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Not yet recruiting
N/A
100
NA
Bortezomib-bendamustine-melphalan, High-dose melphalan
Uppsala University, Uppsala County Council, Sweden, Dalarna County Council, Sweden
Myeloma Multiple
03/25
09/25
ChiCTR2200059541: A multicenter, open-label, single-arm clinical study of the safety and efficacy of selinexol, bendamustine, bortezomib, and dexamethasone (X-BenBD) regimen in the treatment of primary/secondary extramedullary plasmacytoma

Not yet recruiting
N/A
25
 
selinexor, bendamustine, bortezomib, and dexamethasone
Chongqing Xinqiao Hospital; Chongqing Xinqiao Hospital, self-funded
Multiple Myeloma (MM)
 
 
NCT05899621: A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting
N/A
332
RoW
Obinutuzumab, Lenalidomide, Bendamustine, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Ruijin Hospital
Follicular Lymphoma
06/25
06/27
ChiCTR2100054730: Efficacy and safety of autologous hematopoietic stem cell transplantation with BGB regimen (Busulfan + Gemcitabine + Bendamustine) for patients with replased/refractory non-Hodgkin's lymphoma: a prospective, single arm, open lable study

Recruiting
N/A
119
 
received BGB regimen
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Nature Science Fund 81873446
Non-Hodgkin’s lymphome
 
 
NCT05406154: Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Recruiting
N/A
60
RoW
Peking University Third Hospital, Peking Union Medical College Hospital, The Second Affiliated Hospital of Dalian Medical University, Peking University First Hospital, Beijing Tongren Hospital, Beijing Hospital, Beijing Tsinghua Changgeng Hospital, China-Japan Friendship Hospital, 307 Hospital of PLA, Chinese PLA General Hospital, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Baotou Cancer Hospital, Beijing Shijitan Hospital, Capital Medical University, Shanxi Province Cancer Hospital, Beijing Naval General Hospital, First Hospital of China Medical University, Jilin Provincial Tumor Hospital, Shengjing Hospital
Mantle Cell Lymphoma (MCL)
12/23
07/24
NCT05506410: A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

Recruiting
N/A
100
RoW
Rituximab, Bendamustine, Cytarabine, Prednisone, BTK inhibitors
Zhengzhou University
Newly Diagnosed Mantle Cell Lymphoma
06/24
12/26
 

Download Options